1. SEER Stat Fact Sheets: Chronic Myeloid Leukemia. National Cancer Institute 2012. http://seer.cancer.gov/statfacts/html/cmyl.html
2. The Canadian Coordinating Office for Health Technology Assessment: Issues in emerging Health Technologies. Imatimib Mesylate for Chronic Myeloid Leukemia: What do we really know? http://www.cadth.ca/media/pdf/192_imatinib_cetap_e.pdf
3. Dalziel K, Round A, Stein K, et al.: Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004,8(28):1–120.
4. Baccarani M: Clinical implications of the recommendations of the European LeukemiaNet. Presented at 14th Congress of the European Hematology Association, Berlin, 4–7 June, 2009
5. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. 2009; (v.2.2010) http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf